Evolus (EOLS)
7.91
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 10-Q Evolus, Inc. For: Jun 30
August 5, 2026 4:57 PM - SEC Filing
Form 8-K Evolus, Inc. For: Aug 05
August 5, 2026 4:21 PM - SEC Filing
Evolus (EOLS) Misses Q2 EPS by 8c; Offers Guidance
August 5, 2026 4:17 PM - StreetInsider
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
August 5, 2026 4:05 PM - BizWire
Form 8-K Evolus, Inc. For: Aug 03
August 4, 2026 8:46 AM - SEC Filing
Evolus expands Symatese deal to sell Estyme in Canada and Oceania
August 4, 2026 8:30 AM - StreetInsider
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
August 4, 2026 8:30 AM - BizWire
Evolus to Report Second Quarter Financial Results on August 5, 2026
July 22, 2026 8:30 AM - BizWire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026 4:05 PM - BizWire
Form 8-K Evolus, Inc. For: Jul 07
July 8, 2026 9:04 AM - SEC Filing
Evolus strikes licensing deal with IBSA to bring Profhilo to US
July 8, 2026 9:02 AM - StreetInsider
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
July 8, 2026 9:00 AM - BizWire
Full Article List
